Detalles de la búsqueda
1.
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
Bioorg Med Chem Lett
; 74: 128928, 2022 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35961460
2.
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors.
Bioorg Med Chem Lett
; 74: 128929, 2022 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35961461
3.
Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
Biochemistry
; 55(38): 5434-41, 2016 09 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-27571378
4.
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
Mol Cancer Ther
; 20(11): 2098-2109, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34433663
5.
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Cancer Cell
; 35(5): 738-751.e9, 2019 05 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31085175
6.
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.
Mol Cancer Ther
; 14(9): 2023-34, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26285778
7.
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Cancer Cell
; 28(3): 384-98, 2015 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26343583
8.
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
J Med Chem
; 58(10): 4165-79, 2015 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-25965804
Resultados
1 -
8
de 8
1
Próxima >
>>